USA flag logo/image

An Official Website of the United States Government

NOVEL BASE BORONATED OLIGONUCLEOTIDES FOR BORON NEUTRON CAPTURE THERAPY

Award Information

Agency:
Department of Energy
Branch:
N/A
Award ID:
10814
Program Year/Program:
1990 / SBIR
Agency Tracking Number:
10814
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BORON BIOLOGICALS, INC.
620 HUTTON ST, STE 104 RALEIGH, NC 27606
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1990
Title: NOVEL BASE BORONATED OLIGONUCLEOTIDES FOR BORON NEUTRON CAPTURE THERAPY
Agency: DOE
Contract: N/A
Award Amount: $499,885.00
 

Abstract:

BORON NEUTRON CAPTURE THERAPY (BNCT) HAS A CLEAR THEORETICALADVANTAGE OVER OTHER TECHNIQUES AS A METHOD OF DELIVERING CELL KILLING RADIATION TO TUMORS. NEW BORON COMPOUNDS ARE NEEDED THAT CAN SELECTIVELY LOCALIZE IN TUMORS AND, UPON CAPTURE OF THERMAL OR EPITHERMAL NEUTRONS, PRODUCE RADIATIONTO KILL TUMOR CELLS BUT SPARE NORMAL TISSUE AND BLOOD. BNCTEFFECTIVENESS WOULD BE GREATEST IF THE BORON TARGETED THE CELL NUCLEUS AND LOWER CONCENTRATIONS COULD BE USED. PHASE I WILL SYNTHESIZE BORONATED OLIGONUCLEOTIDES THAT ARE RESISTANT TO NUCLEASES AND THAT SHOULD READILY ENTER CELLS AND TARGET (BY AN "ANTISENSE" MECHANISM) THE DNA OR RNA NUCLEAR MATERIAL OF TUMOR CELLS. THE OLIGONUCLEOTIDES WILL BE PREPARED BOTH CHEMICALLY AND ENZYMATICALLY USING NUCLEOSIDES THAT HAVE BEEN BORONATED ON BASE POSITIONS, AFFECTING BASE PAIRING ABILITIES AND OTHER NORMAL ACTIVITY ONLY MINIMALLY (IF AT ALL). OF CONSIDERABLE ADDED VALUE IS THE EXPECTED ANTI-TUMOR ACTIVITY OF THE BORONATED OLIGONUCLEOTIDES IN ADDITION TO THAT PROVIDED BY BNCT.

Principal Investigator:

Dr Bernard F Spielvogel
Principal Investigator
9198322044

Business Contact:

Small Business Information at Submission:

Boron Biologicals Inc.
2811 O'berry St Raleigh, NC 27607

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No